Browsing Tag
Tirzepatide
30 posts
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.
Cirius Therapeutics shows 0602K and tirzepatide combo preserves muscle and burns fat in obesity and type 2 diabetes
Cirius Therapeutics unveils new ADA 2025 data showing MPC inhibitor 0602K significantly improves muscle and fat metabolism when combined with tirzepatide.
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
Gan & Lee Pharmaceuticals begins US Phase 2 trial of bofanglutide for obesity and weight management
Gan & Lee Pharmaceuticals (Shanghai Stock Exchange: 603087) has initiated its Phase 2 clinical trial of bofanglutide (GZR18)…
More affordable Zepbound? Lilly’s new pricing plan shakes up obesity treatment
Eli Lilly and Company (Lilly) has introduced new single-dose vials of Zepbound (tirzepatide), expanding treatment options for self-pay…
Palatin Technologies completes Phase 2 obesity trial with MC4R bremelanotide and GLP-1/GIP tirzepatide
Palatin Technologies, Inc. has announced the completion of its Phase 2 BMT-801 clinical trial, a study evaluating the…
Why BioAge Labs’ promising obesity drug trial of azelaprag came to an abrupt halt
BioAge Labs, a clinical-stage biopharmaceutical company focused on metabolic disease research, has announced the discontinuation of its STRIDES…
This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment
Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide…